|
Our patients often benefit by the facts that we are an established, successful, infertility diagnostic and treatment center staffed by board certified reproductive endocrinologists, infertility specialists and also that we participate in ongoing research. Research is the cornerstone to all future advances in the field of reproductive endocrinology and infertility. We recruit patients for many of these studies and those meeting the inclusion criteria are encouraged to submit their information.
As we acquire new studies, or close finished protocols, we will list the status on this Web page.
Clinical Research Studies Recruiting or Underway:
Clinical Study Participation Available Through RCC
GSN single gene testing plus 24-chromosome aneuploidy screening clinical study.
Gene Security Network is currently accepting participants for a clinical study that will apply GSN’s proprietary Parental Support™ Technology to detect single-gene disorders AND aneuploidy in Day 3 embryos in time for a Day 5 transfer. If a couple qualifies for the study, there will be no charge for the testing. Study details can be accessed at www.clinicaltrials.gov.
Inclusion criteria include but are not limited to:
• Embryo at-risk for recognized single-gene disease
• Maternal age < 40
• FSH </= 10
• Planning to pursue prenatal diagnosis through CVS or amniocentesis
• Documented mutation report from a CLIA-certified laboratory
Couples of any ethnicity who are at risk for:
• Sickle cell disease
• Beta-thalassemia
• Cystic fibrosis
• Fragile X
• Friedrich’s ataxia
• Huntington disease
• Myotonic dystrophy
• Duchenne muscular dystrophy
• Hemophilia A
• Alpha-thalassemia
• Hereditary breast cancer (BRCA1/2) |
Ashkenazi Jewish couples at risk for the following:
• Tay-Sachs
• Canavan disease
• Cystic fibrosis
• Glycogen storage disease type 1A
• Bloom syndrome
• Familial dysautonomia
• Fanconi anemia group C
• Niemann-Pick Type A
• Usher syndrome Type III, 1F
• Mucolipidosis IV
• Maple syrup urine disease, type 1B, 3 |
More information about this study.
|
